Recommended Topic Related To:

Khedezla

"Everyone occasionally feels blue or sad. But these feelings are usually short-lived and pass within a couple of days. When you have depression, it interferes with daily life and causes pain for both you and those who care about you. Depression is"...

Khedezla

Khedezla Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Khedezla (desvenlafaxine) is a type of antidepressant called a serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD). Common side effects include sleepiness, dizziness, loss of appetite, insomnia, anxiety, sweating, decreased sex drive, constipation, delayed orgasm and ejaculation.

The recommended dose for Khedezla is 50 mg once daily, with or without food. Khedezla may interact with monoamine oxidase inhibitors (MAOIs), other antidepressants, metoclopramide, silbutramine, tramadol, St. John's Wort, tryptophan supplements, and medicines used to treat mood, anxiety, psychotic, or thought disorders. Tell your doctor all medications and supplements you use. It is unknown if Khedezla will harm a fetus. Tell your doctor if you are pregnant or plan to become pregnant while taking Khedezla. This drug can pass into breast milk and may harm a nursing baby. Consult your doctor before breastfeeding.

Our Khedezla (desvenlafaxine) Extended-release Tablets Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Khedezla FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The following adverse reactions are discussed in greater detail in other sections of the label.

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.

Patient Exposure

Desvenlafaxine was evaluated for safety in 4,158 patients diagnosed with major depressive disorder who participated in multiple-dose pre-marketing studies, representing 1,677 patient-years of exposure. Among these 4,158 desvenlafaxine treated patients; 1,834 patients were exposed to desvenlafaxine in 8-week, placebo-controlled studies at doses ranging from 50 to 400 mg/day. Out of the 1,834 patients, 687 desvenlafaxine treated patients continued into a 10-month open-label study. Of the total 4,158 patients exposed to at least one dose of desvenlafaxine; 1,320 were exposed to desvenlafaxine for 6 months, representing 1058 patient-years of exposure, and 274 were exposed for one year, representing 241 patient-years of exposure.

Adverse Reactions Reported As Reasons For Discontinuation Of Treatment

In the pooled 8-week placebo-controlled studies in patients with MDD, 12% of the 1,834 patients who received desvenlafaxine (50 to 400 mg) discontinued treatment due to an adverse reaction, compared with 3% of the 1,116 placebo-treated patients. At the recommended dose of 50 mg, the discontinuation rate due to an adverse reaction for desvenlafaxine (4.1%) was similar to the rate for placebo (3.8%). For the 100 mg dose of desvenlafaxine the discontinuation rate due to an adverse reaction was 8.7%.

The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the desvenlafaxine treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each); in the longer-term studies, up to 11 months, the most common was vomiting (2%).

Common Adverse Reactions In Placebo-Controlled MDD Studies

The most commonly observed adverse reactions in desvenlafaxine treated MDD patients in short-term fixed-dose studies (incidence ≥ 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.

Table 2 shows the incidence of common adverse reactions that occurred in ≥ 2% of desvenlafaxine treated MDD patients and twice the rate of placebo at any dose in the pooled 8-week, placebo-controlled, fixed dose clinical studies

Table 2: Common Adverse Reactions ( ≥ 2% in any Fixed-Dose Group and Twice the Rate of Placebo) in Pooled MDD 8-Week Placebo-Controlled Studies

System Organ Class Preferred Term Placebo
(n=636)
Percentage of Patients Reporting Reaction
50 mg
(n=317)
100 mg
(n=424)
200 mg
(n=307)
400 mg
(n=317)
Cardiac disorders
  Blood pressure increased 1 1 1 2 2
Gastrointestinal disorders
  Nausea 10 22 26 36 41
  Dry mouth 9 11 17 21 25
  Constipation 4 9 9 10 14
  Vomiting 3 3 4 6 9
General disorders and administration site conditions
  Fatigue 4 7 7 10 11
  Chills 1 1 < 1 3 4
  Feeling jittery 1 1 2 3 3
Metabolism and nutrition disorders
  Decreased appetite 2 5 8 10 10
Nervous system disorders
  Dizziness 5 13 10 15 16
  Somnolence 4 4 9 12 12
  Tremor 2 2 3 9 9
  Disturbance in attention < 1 < 1 1 2 1
Psychiatric disorders
  Insomnia 6 9 12 14 15
  Anxiety 2 3 5 4 4
  Nervousness 1 < 1 1 2 2
  Abnormal dreams 1 2 3 2 4
Renal and urinary disorders
  Urinary hesitation 0 < 1 1 2 2
  Respiratory, thoracic and mediastinal disorders
Yawning < 1 1 1 4 3
Skin and subcutaneous tissue disorders
  Hyperhidrosis 4 10 11 18 21
Special Senses
  Vision blurred 1 3 4 4 4
  Mydriasis < 1 2 2 6 6
  Vertigo 1 2 1 5 3
  Tinnitus 1 2 1 1 2
  Dysgeusia 1 1 1 1 2
Vascular disorders
  Hot flush < 1 1 1 2 2

Sexual Function Adverse Reactions

Table 3 shows the incidence of sexual function adverse reactions that occurred in ≥ 2% of desvenlafaxine treated MDD patients in any fixed-dose group (pooled 8-week, placebo-controlled, fixed and flexible-dose, clinical studies).

Table 3: Sexual Function Adverse Reactions ( ≥ 2% in Men or Women in any Desvenlafaxine Group) During the On-Therapy Period

  Placebo
(n=239)
Desvenlafaxine
50 mg
(n=108)
100 mg
(n=157)
200 mg
(n=131)
400 mg
(n=154)
Men only
  Anorgasmia 0 0 3 5 8
  Libido decreased 1 4 5 6 3
  Orgasm abnormal 0 0 1 2 3
  Ejaculation delayed < 1 1 5 7 6
  Erectile dysfunction 1 3 6 8 11
  Ejaculation disorder 0 0 1 2 5
  Ejaculation failure 0 1 0 2 2
  Sexual dysfunction 0 1 0 0 2
  Placebo
(n=397)
Desvenlafaxine
50 mg
(n=209)
100 mg
(n=267)
200 mg
(n=176)
400 mg
(n=163)
Women only
  Anorgasmia 0 1 1 0 3

Other Adverse Reactions Observed In Clinical Studies

Other infrequent adverse reactions, not described elsewhere in the label, occurring at an incidence of < 2% in MDD patients treated with desvenlafaxine were:

Cardiac disorders - tachycardia.

General disorders and administration site conditions - Asthenia.

Investigations - Weight increased, liver function test abnormal, blood prolactin increased.

Musculoskeletal and connective tissue disorders - Musculoskeletal stiffness.

Nervous system disorders -Syncope, convulsion, dystonia.

Psychiatric disorders - Depersonalization, bruxism.

Renal and urinary disorders - Urinary retention.

Skin and subcutaneous tissue disorders - Rash, alopecia, photosensitivity reaction, angioedema.

In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during desvenlafaxine treatment as compared to placebo.

Laboratory, ECG And Vital Sign Changes Observed In MDD Clinical Studies

The following changes were observed in placebo-controlled, short-term MDD studies with desvenlafaxine.

Lipids

Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potentially clinically significant.

The percentage of patients who exceeded a predetermined threshold value is shown in Table 4.

Table 4: Incidence (%) of Patients With Lipid Abnormalities of Potential Clinical Significance*

  Placebo Desvenlafaxine
50 mg 100 mg 200 mg 400 mg
Total Cholesterol *(Increase of ≥ 50 mg/dl and an absolute value of ≥ 261 mg/dl) 2 3 4 4 10
LDL Cholesterol *(Increase ≥ 50 mg/dl and an absolute value of ≥ 190 mg/dl) 0 1 0 1 2
Triglycerides, fasting *(Fasting: ≥ 327 mg/dl) 3 2 1 4 6

Proteinuria

Proteinuria, greater than or equal to trace, was observed in the fixed-dose controlled studies (see Table 5). This proteinuria was not associated with increases in BUN or creatinine and was generally transient.

Table 5: Incidence (%) of Patients with Proteinuria in the Fixed-dose Clinical Studies

  Placebo Desvenlafaxine
50 mg 100 mg 200 mg 400 mg
Proteinuria 4 6 8 5 7

Vital sign changes

Table 6 summarizes the changes that were observed in placebo-controlled, short-term, pre-marketing studies with desvenlafaxine in patients with MDD (doses 50 to 400 mg).

Table 6: Mean Changes in Vital Signs at Final on Therapy for All Short-term, Fixed-dose Controlled Studies

  Placebo Desvenlafaxine
50 mg 100 mg 200 mg 400 mg
Blood pressure
Supine systolic bp (mm Hg) -1.4 1.2 2.0 2.5 2.1
Supine diastolic bp (mm Hg) -0.6 0.7 0.8 1.8 2.3
Pulse rate
Supine pulse (bpm) -0.3 1.3 1.3 0.9 4.1
0.0 -0.4 -0.6 -0.9 -1.1

Treatment with desvenlafaxine at all doses from 50 mg/day to 400 mg/day in controlled studies was associated with sustained hypertension, defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥ 90 mm Hg and ≥ 10 mm Hg above baseline for 3 consecutive on-therapy visits (see Table 7). Analyses of patients in desvenlafaxine short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension. This was seen at all doses with a suggestion of a higher rate at 400 mg/day.

Table 7: Proportion of Patients with Sustained Elevation of Supine Diastolic Blood Pressure

Treatment Group Proportion of Patients with Sustained Hypertension
Placebo 0.5%
Desvenlafaxine 50 mg/day 1.3%
Desvenlafaxine 100 mg/day 0.7%
Desvenlafaxine 200 mg/day 1.1%
Desvenlafaxine 400 mg/day 2.3%

Orthostatic hypotension

In the short-term, placebo-controlled clinical studies with doses of 50 to 400 mg, systolic orthostatic hypotension (decrease ≥ 30 mm Hg from supine to standing position) occurred more frequently in patients ≥ 65 years of age receiving desvenlafaxine (8%, 7/87) versus placebo (2.5%, 1/40), compared to patients < 65 years of age receiving desvenlafaxine (0.9%, 18/1,937) versus placebo (0.7%, 8/1,218).

Postmarketing Experience

The following adverse reaction has been identified during post-approval use of desvenlafaxine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Skin and subcutaneous tissue disorders -Stevens-Johnson syndrome.

Read the entire FDA prescribing information for Khedezla (Desvenlafaxine Extended-release Tablets) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Emotional Wellness

Get tips on therapy and treatment.